Vedroprevir

Drug Profile

Vedroprevir

Alternative Names: GS-9451; VDV

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Gilead Sciences
  • Class Amides; Antivirals; Carbamates; Carboxylic acids; Cyclopentanes; Cyclopropanes; Hydroxyquinolines; Macrocyclic compounds; Morpholines; Pyrrolidines; Thiazoles
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 01 Feb 2015 Gilead Sciences completes a phase II trial for Hepatitis C (Combination therapy) in USA (NCT02226549)
  • 07 Oct 2014 Gilead Sciences completes enrolment in a phase II trial in Hepatitis C (Combination therapy) in USA (NCT02226549)
  • 01 Jul 2014 Phase-II clinical trials in Hepatitis C (Combination therapy, Treatment-experienced) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top